Biotech Earnings Roundup: Key Finance Stories From GILD, MRNA, and AMGN

The Q1 2026 biotech earnings cycle brought three of the sector's largest companies into focus at the same time, with results that illustrate divergent strategies for managing growth. Gilead Sciences (GILD) reported a combination of franchise momentum and aggressive pipeline investment that produced both raised revenue guidance and a projected full-year loss. Moderna (MRNA) and Amgen (AMGN) each added data points to a sector landscape where near-term earnings pressure and long-term pipeline commitments are running simultaneously.

Gilead's Top Line: Core Business Separates From COVID Revenue

Gilead Sciences reported total product sales of $6.9 billion in Q1 2026, a 5% increase year over year. The headline figure includes Veklury, the company's COVID-19 antiviral, which adds meaningful volatility to period comparisons as pandemic-related demand has normalized. Excluding Veklury, the base business reached $6.8 billion, up 8% from the prior-year period.

That distinction carries analytical weight. The 8% growth rate in the ex-Veklury base reflects sustained demand across HIV treatments, oncology, and liver disease products rather than residual pandemic volume. It provides a cleaner read on the company's underlying commercial trajectory heading into the balance of 2026.

HIV Franchise: Biktarvy Holds Market Share, Yes2Go Accelerates

Biktarvy, Gilead's HIV treatment, generated $3.4 billion in Q1 2026 and maintained more than 52% of the U.S. HIV treatment market. The drug has consistently held its position as the most prescribed HIV regimen in the United States, and that share level, sustained at this scale, represents a significant foothold in the category.

Yes2Go, an injectable PrEP option approved in late 2025, reported Q1 2026 sales of $166 million, up 72% from the prior quarter. Management cited specific access metrics as indicators of durability: 95% of commercial insurance plans cover Yes2Go, and 95% of covered patients face zero out-of-pocket copay. Gilead projects the drug will reach $1 billion in sales in its first full year on the market, which would meet the standard threshold for a blockbuster product.

The access metrics matter because PrEP uptake is historically sensitive to cost and coverage barriers. When patients can fill a prescription without a copay and pharmacies can bill through established insurance pathways, adoption curves tend to steepen. Gilead's decision to frame the 95% coverage figure alongside the 72% quarter-over-quarter growth rate suggests management views the coverage structure as a key driver of Yes2Go's sales trajectory.

Based on these results, Gilead raised its full-year HIV growth guidance from 6% to 8%. The revision incorporates both Biktarvy's continued market position and Yes2Go's faster-than-anticipated commercial uptake in its first full quarter following launch.

Three Acquisitions, $11.5 Billion in Upfront Costs

Gilead closed three acquisitions during the period: Arcellx, which is developing anitocel, a CAR-T cell therapy in clinical trials for relapsed or refractory multiple myeloma; Tubulis, which contributes an antibody-drug conjugate platform for targeted oncology applications; and Oral Medicines, a company focused on autoimmune treatments delivered via oral formulations. Together, the three transactions carried approximately $11.5 billion in combined upfront costs.

That level of spending has a direct accounting consequence. Gilead is projecting a per-share loss for full-year 2026, driven by the recognition of acquisition-related charges through the income statement. A portion of those charges are non-cash, tied to the accounting treatment of acquired in-process research and development assets, but they nonetheless reduce reported earnings per share for the year. Management described the combined portfolio as a multi-platform expansion across oncology, immunology, and targeted therapy.

The trade-off is visible in the numbers: a franchise generating billions in quarterly revenue funding a $11.5 billion bet on the next phase of product development, with the upfront cost flowing through current-year earnings. Listeners tracking the full management commentary on acquisition rationale and pipeline timelines can find the Q1 discussion in the Gilead Q1 2026 earnings breakdown at /podcasts/GILD_Q1_2026.

Moderna and Amgen: Context From the Broader Earnings Window

Moderna (MRNA) and Amgen (AMGN) both reported Q1 2026 results during the same earnings window, each reflecting a different strategic phase. Moderna has been managing the post-pandemic transition of its revenue base, working to validate its mRNA platform across programs including influenza, RSV, and oncology vaccines, while its COVID-19 product continues to generate the majority of current commercial revenue. Amgen, with an established portfolio of biologics across inflammation, oncology, and cardiovascular disease, entered Q1 facing its own dynamics around biosimilar competition and the integration of significant recent acquisitions.

Both companies represent different positions on the pipeline-investment spectrum. Moderna's pipeline is largely in clinical development, meaning near-term revenue depends heavily on COVID vaccine demand while longer-duration programs accumulate in trials. Amgen's diversified commercial base provides a different financial profile, with established products generating cash flow that funds both shareholder returns and pipeline investment. Full breakdowns of each company's quarter are available at the Moderna Q1 2026 earnings breakdown at /podcasts/MRNA_Q1_2026 and the Amgen Q1 2026 earnings breakdown at /podcasts/AMGN_Q1_2026.

Balancing Current Performance Against Pipeline Commitments

The Q1 2026 biotech cycle makes a recurring sector dynamic legible in concrete terms. Companies with strong, cash-generating franchises are deploying that cash into pipeline expansion, accepting near-term earnings pressure in exchange for longer-duration asset development. Gilead's situation is the clearest illustration: the base business generated $6.8 billion in a single quarter, and the company simultaneously committed $11.5 billion in upfront acquisition costs to extend its pipeline into CAR-T, antibody-drug conjugate technology, and autoimmune medicine.

The consequence of that sequencing is a projected full-year per-share loss for 2026, even as the underlying commercial franchise grows and HIV guidance moves higher. Each company reporting this cycle is navigating the same fundamental question from a different starting position: how much current-year earnings dilution is the portfolio accepting, in exchange for what type of longer-duration pipeline asset, and on what clinical and regulatory timeline does that investment mature. The Q1 figures provide the current state of each company's answer.

• Gilead Q1 2026 total product sales: $6.9 billion, up 5% year over year
• Base business excluding Veklury: $6.8 billion, up 8%
• Biktarvy: $3.4 billion in Q1 2026, over 52% U.S. HIV treatment market share
• Yes2Go: $166 million in Q1 2026, up 72% quarter over quarter; 95% insurance coverage with 95% of covered patients at zero copay; projected $1 billion in first full year on market
• Full-year HIV growth guidance raised from 6% to 8%
• Acquisitions of Arcellx, Tubulis, and Oral Medicines: approximately $11.5 billion in combined upfront costs
• Gilead projecting a per-share loss for full-year 2026 due to acquisition-related charges